Učitavanje...
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
OBJECTIVE: Add‐on cannabidiol (CBD) significantly reduced seizures associated with Dravet syndrome (DS) in a randomized, double‐blind, placebo‐controlled trial: GWPCARE1 Part B (NCT02091375). Patients who completed GWPCARE1 Part A (NCT02091206) or Part B, or a second placebo‐controlled trial, GWPCAR...
Spremljeno u:
| Izdano u: | Epilepsia |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7379690/ https://ncbi.nlm.nih.gov/pubmed/30582156 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/epi.14628 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|